成纤维细胞生长因子9:治疗精神神经疾病药物新靶点  

Fibroblast growth factor 9:a new target for psychoneurological disorders

作　　者：赵丞 王小青 王宇红[1] 姜德建 ZHAO Cheng;WANG Xiao-qing;WANG Yu-hong;JIANG De-jian(Science and Technology Innovation Research Center,Hunan University of Chinese Medicine&Hunan Key Laboratory of Traditional Chinese Medicine for the Prevention and Treatment of Depressive Diseases,Changsha 410208;Hunan Center for Safety Evaluation and Research of Drugs&Hunan Key Laboratory of Pharmacodynamics and Safety Evaluation of New Drugs,Changsha 410331)

机构地区：[1]湖南中医药大学科技创新中心&抑郁类疾病中医药防治湖南省重点实验室,长沙410208 [2]湖南省药物安全评价研究中心&新药药效与安全性评价湖南省重点实验室,长沙410331

出　　处：《中南药学》2023年第11期2964-2968,共5页Central South Pharmacy

基　　金：湖南省药物非临床研究科技创新创业团队(No.2021)。

摘　　要：成纤维细胞生长因子9(FGF9)是一种能调节细胞增殖、分化和凋亡的生长因子,为成纤维细胞生长因子家族的重要一员。FGF9在人体的细胞和组织中广泛分布,在骨骼、胚胎的发育、血管形成、神经再生、肿瘤生长过程中发挥作用。近年来,随着其在抑郁症、帕金森病、阿尔茨海默病、癫痫、焦虑症等精神神经疾病发病机制中的关键作用不断被认识,FGF9被认为是一个潜在的治疗精神神经疾病药物开发的新靶点。Fibroblast growth factor 9(FGF9)is a growth factor that can regulate the cell proliferation,differentiation and apoptosis,and is an important member of the fibroblast growth factor family.FGF9 is widely distributed in human cells and tissues and plays a role in the bone and embryonic development,blood vessel formation,nerve regeneration and tumor growth.In recent years,with the increasing recognition of its key role in the pathogenesis of neuropsychiatric diseases such as depression,Parkinson’s disease,Alzheimer’s disease,epilepsy and anxiety,FGF9 has been considered as a new potential target for drug development for neuropsychiatric diseases.

关 键 词：成纤维细胞生长因子9 神经精神疾病 药物开发 

分 类 号：R971[医药卫生—药品]